Press

Mydecine Announces Debt Settlements

Mar 6 • 2 min read

Mydecine Innovations Group Inc. (NEO:MYCO | OTC:MYCOF | FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce share for debt settlements for debt owed to certain arms-length creditors, service providers and debtors of the…

Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership

Mar 6 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF |OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, and PharmAla Biotech Holdings Inc (CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, today announced…

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Mar 6 • 5 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates. “The dosing of the first patient in the phase 2b study of RL-007 in CIAS earlier this quarter exemplifies the execution capabilities of our team as we advance our programs into…

PanGenomic Health Provides Corporate Update

Mar 3 • 3 min read

PanGenomic Health Inc. (CSE: NARA), is pleased to provide a corporate update on its strategic initiatives. Acquisition of Mindleap Health Inc. In December 2022, the Company completed the acquisition of Mindleap Health Inc. (“Mindleap”) and its Mindleap app (the “Mindleap App”). The Mindleap App is a virtual health and inner wellness platform that supports its users’…

PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences

Mar 3 • 3 min read

PharmAla Biotech Holdings Inc.(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) are pleased to announce that PharmAla has been named the exclusive MDMA supplier to Awakn LS Europe Holdings Limited (CSE:AWKN). “We’ve been working with the Awakn team for several months now, to ensure they…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435